Y
Yves Durocher
Researcher at National Research Council
Publications - 195
Citations - 8369
Yves Durocher is an academic researcher from National Research Council. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 43, co-authored 169 publications receiving 7139 citations. Previous affiliations of Yves Durocher include University of Saskatchewan & Université de Montréal.
Papers
More filters
Journal ArticleDOI
High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells
TL;DR: A scalable transfection procedure using polyethylenimine (PEI) is described for the human embryonic kidney 293 cell line grown in suspension and 10- and 3-fold increases in SEAP expression was obtained in 293E cells compared with pcDNA3.1 and pCEP4 vectors.
Journal ArticleDOI
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
Baweleta Isho,Kento T. Abe,Kento T. Abe,Michelle Zuo,Alainna J Jamal,Alainna J Jamal,Bhavisha Rathod,Jenny Wang,Zhijie Li,Gary Chao,Olga L. Rojas,Yeo Myong Bang,Annie Pu,Natasha Christie-Holmes,Christian Gervais,Derek F. Ceccarelli,Payman Samavarchi-Tehrani,Furkan Guvenc,Patrick Budylowski,Angel Li,Aimee Paterson,Feng Yun Yue,Lina María Marín,Lauren Caldwell,Jeffrey L. Wrana,Jeffrey L. Wrana,Karen Colwill,Frank Sicheri,Frank Sicheri,Samira Mubareka,Scott D. Gray-Owen,Steven J. Drews,Walter L. Siqueira,Miriam Barrios-Rodiles,Mario A. Ostrowski,Mario A. Ostrowski,James M. Rini,Yves Durocher,Allison McGeer,Allison McGeer,Allison McGeer,Jennifer L. Gommerman,Anne-Claude Gingras,Anne-Claude Gingras +43 more
TL;DR: It is confirmed that serum and saliva IgG antibodies to SARS-CoV-2 are maintained in the majority of COVID-19 patients for at least 3 months PSO, and IgG responses in saliva may serve as a surrogate measure of systemic immunity to Sars-Cov-2 based on their correlation with serum IgG responds.
Journal ArticleDOI
Expression systems for therapeutic glycoprotein production.
Yves Durocher,Michael Butler +1 more
TL;DR: There are slightly over 165 recombinant pharmaceuticals currently approved for human use and another 500 protein candidates are in preclinical and clinical development, about 70% of these being glycosylated proteins, with considerable advantage in producing proteins with enhanced therapeutic properties.
Journal ArticleDOI
MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons
Penka S. Petrova,Andrei A. Raibekas,Jonathan Pevsner,Noel T. Vigo,Mordechai Anafi,Mary K. Moore,Amy E. Peaire,Viji Shridhar,David I. Smith,John F. Kelly,Yves Durocher,John W. Commissiong +11 more
TL;DR: The selective, neuroprotective effect of MANF for dopaminergic neurons suggests that it may be indicated for the treatment of Parkinson's disease.
Journal ArticleDOI
Nuclear localization of prostaglandin E2 receptors
Mousumi Bhattacharya,Krishna G. Peri,Guillermina Almazan,A. Ribeiro-da-Silva,Hitoshi Shichi,Yves Durocher,Mark Abramovitz,Xin Hou,Daya R. Varma,Sylvain Chemtob +9 more
TL;DR: High-resolution immunostaining of EP1 revealed their presence in the nuclear envelope of isolated (cultured) endothelial cells and in situ in brain (cortex) endothelium cells and neurons.